ADCs and their Drug Development Process

“One of the fastest-growing modalities in the pharmaceutical industry, antibody-drug conjugates (ADCs), combines a targeted antibody with a cytotoxic payload to offer numerous therapeutic benefits. Veranova’s experts have a deep understanding of the challenges involved in ADC development and have explored how advanced techniques such as preparative chromatography can help streamline the process.”

In this Q&A in Pharma Focus Europe, Veranova’s Global VP, AR&D Lab Operations, Dr. Kishore Hotha, discusses the current ADC landscape, their therapeutic potential and the challenges faced during development.


Veranova is your next great decision

Discover new ways to advance your science with Veranova.

Contact us